UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014668
Receipt number R000017061
Scientific Title A Randomized Controlled Trial compares the efficacy of Moviprep vs Muben on the bowel preparation of the patients who undergo colorectal endoscopic submucosal dissection
Date of disclosure of the study information 2014/08/15
Last modified on 2017/01/28 09:41:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized Controlled Trial compares the efficacy of Moviprep vs Muben on the bowel preparation of the patients who undergo colorectal endoscopic submucosal dissection

Acronym

MOVI STUDY

Scientific Title

A Randomized Controlled Trial compares the efficacy of Moviprep vs Muben on the bowel preparation of the patients who undergo colorectal endoscopic submucosal dissection

Scientific Title:Acronym

MOVI STUDY

Region

Japan


Condition

Condition

Colorectal tumor

Classification by specialty

Gastroenterology Nursing

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To compare the effect of Moviprep (low-volume colonoscopy prep) and Muben (standard-volume) on the bowel preparation for the patients undergo colorectal endoscopic submucosal dissection.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Preparation time

Key secondary outcomes

Boston Bowel Preparation Scale score, acceptability, taste, frequencies of stool, total volume of the prep, complication rate.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Moviprep 1.5L ~ 2L

Interventions/Control_2

Muben 3L ~ 4L

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients who underwent colorectal endoscopic submucosal dissection (ESD) at National Cancer Center Hospital.
1. Indication for colorectal ESD
2. Irrespective of number of the lesion
3. Age from 20 years old to 75 years old
4. Performance status 0, 1, 2
5. Patients who has written informed consent for this study

Key exclusion criteria

1. Patients having risk of perforation, obstruction and suspicious of ileum.
2. Toxic megacolon
3. Allergy for Moviprep and Muben
4. Dehydration
5. Mental disease
6. Without written informed consent
7. Angina pectoris and/or past history of myocardial infarction within 6 months.
8. Active inflammatory bowel diseases
9. Past history of convulsive attack
10. Serum creatinine level &#8805;1.3 mg/dL
11. Others (depends on the chief physician)

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takahisa Matsuda

Organization

National Cancer Center Hospital

Division name

Endoscopy Division

Zip code


Address

5-1-1, Tsukiji, Chuo-ku, Tokyo

TEL

+81-3-3542-2511

Email

tamatsud@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masayoshi Yamada

Organization

National Cancer Center Hospital

Division name

Endoscopy Division

Zip code


Address

5-1-1, Tsukiji, Chuo-ku, Tokyo

TEL

+81-3-3542-2511

Homepage URL


Email

masyamad@ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

Ajinomoto Pharmaceuticals Co., LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター中央病院


Other administrative information

Date of disclosure of the study information

2014 Year 08 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 07 Month 20 Day

Date of IRB


Anticipated trial start date

2014 Year 08 Month 15 Day

Last follow-up date

2015 Year 08 Month 15 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 07 Month 28 Day

Last modified on

2017 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017061


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name